Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus

ConclusionsTo support decision making following progression to immunotherapy-based treatment in patients with advanced wild-type lung adenocarcinoma, a consensus document has been developed.
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

ConclusionOur findings confirm pericardial effusion as a relatively frequent side effect of immunotherapy in NSCLC. Clinicians should be aware of this specific toxicity in patients with metastatic NSCLC receiving immunotherapy and refer to a cardiologist for a multidisciplinary approach.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
Abstract The involvement of immune dysfunction in the pathogenesis of lung cancer has been extensively studied. However, the potential molecular mechanisms through which the tumor immune response affects drug resistance are still unclear. Accordingly, in this study, we evaluated deviations in the immune cell landscape among patients with different stages of lung adenocarcinoma to identify key microRNAs and their targets associated with patient outcomes. CIBERSORT was used for estimating the proportions of immune cells in various lung tissues. Significantly different adaptive and innate immune cell types, including...
Source: Biomed Res - Category: Research Authors: Tags: Biomed Res Int Source Type: research
A new radiomics technique can determine which lung cancer patients will benefit...Read more on AuntMinnie.comRelated Reading: AI, radiomics predict prostate cancer aggressiveness CT radiomics uses immunohistology to detect thyroid cancer AI can improve reproducibility of radiomics in CT Can radiomics detect pancreatic ductal adenocarcinoma? AI, radiomics can help predict chemotherapy response
Source: Headlines - Category: Radiology Source Type: news
Conclusion: Bronchoscopic re-biopsy for progressive lung cancer is feasible and safe. Histological change can be detected in a considerable number of patients, which is potentially valuable information for guidance of subsequent treatment.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Lung cancer Source Type: research
We report the case of a 73-year-old patient with advanced lung adenocarcinoma who developed HPD following treatment with a unique dose of atezolizumab for a skin metastasis that was refractory to chemotherapy and radiotherapy. Potential clinical biomarkers related to HPD to ICIs are reviewed.
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: Case Reports Source Type: research
Advancing treatments for complex and deadly diseases needs gene signatures to identify patients at risk under various genetic and clinical conditions. Our new prognosis gene signature for lung adenocarcinoma meets that need with risk ‐stratification ability on mutation status ofEGFR andTP53, levels of immune checkpointPD ‐L1 expression, and with and without adjuvant chemotherapy. This is a helpful step toward selecting an effective, personalized treatment plan for lung adenocarcinoma patients. AbstractThe overall survival rates for lung cancer remain unsatisfactorily low, even for patients with biomarkers for which tar...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
Conclusions: Hypofractionated carbon-ion RT showed excellent local control and overall survival without severe toxicities in lung cancer patients with isolated lymph node metastasis after surgery or carbon-ion RT for primary lung tumors. A multi-institutional prospective study is required to establish the efficacy and safety of carbon-ion RT.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
This case report highlights that multidisciplinary treatment planning is critical for stage IIIb –IV non‐small cell lung cancer (NSCLC) patients in the era of highly effective treatments, including chemotherapy, molecular targeted therapy, and immunotherapy, which may demonstrate treatment‐free remission (TFR) even in highly selected advanced lung cancer patients with poly‐metastases, a nd we need more information about the association between each genetic alteration and the significance of salvage surgery. The prognosis of stage IVb non ‐small cell lung cancer (NSCLC) patients with multiple distant metastase...
Source: Respirology Case Reports - Category: Respiratory Medicine Authors: Tags: Case Report Source Type: research
ConclusionPrimary adenocarcinoma of the jaw is extremely rare, except for 2–3% central mucoepidermoid carcinomas. The possibility of a metastatic tumor should be a consideration when encountering unusual histomorphology of an adenocarcinoma in the jaw bone.
Source: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology - Category: ENT & OMF Source Type: research
Conclusion and outlookThe case presented here is of interest as it adopts a  novel immunotherapeutic approach to HAC, yielding a promising outcome. This highlights the importance of molecular typing and immunohistochemical profiling in the diagnosis and management of non-small cell lung cancer.
Source: Memo - Magazine of European Medical Oncology - Category: Cancer & Oncology Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Chemotherapy | Docetaxel | Immunotherapy | Lung Cancer | Spain Health | Taxotere | Toxicology